OAM
MYGN icon

Oberweis Asset Management’s Myriad Genetics MYGN Stock Holding History

Oberweis Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-360,700
Closed -$9.88M – 226
2024
Q3 		$9.88M Hold
360,700
– – 0.51% 74
2024
Q2 		$8.82M Buy
+360,700
New +$7.91M 0.54% 73
2019
Q1 		– Sell
-8,230
Closed -$239K – 217
2018
Q4 		$239K Buy
8,230
+2,800
+52% +$101K 0.05% 183
2018
Q3 		$250K Sell
5,430
-700
-11% -$31.1K 0.05% 199
2018
Q2 		$229K Buy
+6,130
New +$207K 0.06% 210
2018
Q1 		– Sell
-9,884
Closed -$339K – 238
2017
Q4 		$339K Buy
+9,884
New +$333K 0.08% 195

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Oberweis Asset Management's MYGN Position: Q4 2024 in Review

Oberweis Asset Management sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 360,700 shares — an estimated $9.88M sold.

Oberweis Asset Management first reported a position in MYGN in Q4 2017 and held it in 6 quarters. The position peaked at $9.88M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Oberweis Asset Management reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Oberweis Asset Management sold 360,700 Myriad Genetics shares in Q4 2024, an estimated $9.88M.
  • Oberweis Asset Management first reported a position in Myriad Genetics in Q4 2017 and held it in 6 quarters.
  • Oberweis Asset Management's Myriad Genetics position peaked at $9.88M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Oberweis Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.